New biomass power plant Ingelheim
Boehringer Ingelheim produces its own green energy
Search
EASi-KIDNEY™ Phase III trial for people with CKD
Boehringer Ingelheim's Sandy Sommer on how treatment innovations in CKD can also improve care for connected conditions, including heart failure.
Dubai
Dubai is at the heart of our IMETA region. Explore career development opportunities in the UAE or our 170 locations around the globe.
The digital therapeutic solution halving hospitalization rates
Around 750,000 people live with chronic heart failure in Canada. The Medly program empowers patients with heart failure to manage their condition
Galym Zhunisbekov
Galym Zhunisbekov, a Regional Regulatory Affairs Manager in Eastern Europe, reflects on our philosophy and our impact on millions of lives.
Advances in vectored vaccines for poultry
Vaccine design technologies have made huge advances in recent years. One of the newer categories of vaccine, vectored vaccines, is overcoming challenges that conventional vaccines do not meet.
New exchange platform with Harbin Research Institute
Boehringer Ingelheim and Harbin Veterinary Research Institute set up ‘industry-academia-research’ exchange platform
Building Successful Partnerships in Animal Health
Christoph Vetten, Head of Transactions Animal Health, shares his perspectives on how building successful collaborations can drive innovation.
LastMile – improving through digital
LastMile initiative is an integrated, solutions-driven program seeking to make animal medical resources available in hard-to-reach areas in Africa.
FDA accepts new chronic kidney disease treatment application
FDA accepts new chronic kidney disease treatment application
Employees empower small dairy producers
Boehringer Ingelheim social intrapreneurship helps farmers improve animal welfare and the well-being of rural communities in Southern India.
Their dogs are their world
Corporate social responsibility in Brazil: Volunteer work and animal healthcare donations for homeless people and their pets.